Canagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

References

• Qazi MU , MalikS. Diabetes and cardiovascular disease: original insights from the Framingham Heart Study. Glob Heart, 8(1), 43–48 (2013).
   PubMedGoogle Scholar
• Arnett DK , BlumenthalRS, AlbertMAet al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol., 74(10), e177–e232 (2019).
   PubMed Web of Science ®Google Scholar
• Fihn SD , GardinJM, AbramsJet al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation, 126(25), e354–471 (2012).
   PubMed Web of Science ®Google Scholar
• Abraira C , DuckworthWC, MoritzT, GroupV. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab, 11(2), 150–156 (2009).
   PubMed Web of Science ®Google Scholar
• Patel A , MacmahonSet al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med., 358(24), 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group , GersteinHC, MillerMEet al.Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med., 358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352(9131), 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Zinman B , WannerC, LachinJMet al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N. Engl. J. Med., 373(22), 2117–2128 (2015).
   PubMed Web of Science ®Google Scholar
• Neal B , PerkovicV, MahaffeyKWet al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N. Engl. J. Med., 377(7), 644–657 (2017).
   PubMed Web of Science ®Google Scholar
• Perkovic V , JardineMJ, NealBet al. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N. Engl. J. Med., 380(24), 2295–2306 (2019).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , RazI, BonacaMPet al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N. Engl. J. Med., 380(4), 347–357 (2019).
   PubMed Web of Science ®Google Scholar
• INVOKANA - FDA . https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf
   Google Scholar
• Medscape . FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease. (2019). https://www.medscape.com/viewarticle/919184
   Google Scholar
• Benjamin EJ , BlahaMJ, ChiuveSEet al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation, 135(10), e146–e603 (2017).
   PubMed Web of Science ®Google Scholar
• Cannon CP , PerkovicV, AgarwalRet al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with Type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results From the CREDENCE Trial. Circulation, 141(5), 407–410 (2020).
   PubMed Web of Science ®Google Scholar
• Mcmurray JJV , SolomonSD, InzucchiSEet al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 381(21), 1995–2008 (2019).
   PubMed Web of Science ®Google Scholar
• Carbone S , DixonDL. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with Type 2 diabetes mellitus. Cardiovasc Diabetol, 18(1), 64 (2019).
   PubMedGoogle Scholar
• Pubchem . Canagliflozin hemihydrate. https://pubchem.ncbi.nlm.nih.gov/compound/Canagliflozin-hemihydrate
   Google Scholar
• Drugbank . Canagliflozin. https://www.drugbank.ca/drugs/DB08907
   Google Scholar
• Defronzo RA , NortonL, Abdul-GhaniM. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol., 13(1), 11–26 (2017).
   PubMed Web of Science ®Google Scholar
• Jakher H , ChangTI, TanM, MahaffeyKW. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab. Syndr. Obes., 12, 209–215 (2019).
   PubMed Web of Science ®Google Scholar
• Wilding JP . The role of the kidneys in glucose homeostasis in Type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism, 63(10), 1228–1237 (2014).
   PubMed Web of Science ®Google Scholar
• Mudaliar S , PolidoriD, ZambrowiczB, HenryRR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care, 38(12), 2344–2353 (2015).
   PubMed Web of Science ®Google Scholar
• Wilcox CS . Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension, 75(4), 894–901 (2020).
   PubMed Web of Science ®Google Scholar
• Gilbert RE . Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?Kidney Int., 86(4), 693–700 (2014).
   PubMed Web of Science ®Google Scholar
• Behnammanesh G , DuranteGL, KhannaYP, PeytonKJ, DuranteW. Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: role of heme oxygenase-1. Redox Biol., 32, 101527 (2020).
   PubMed Web of Science ®Google Scholar
• Lamacchia O , SorrentinoMR. Diabetes Mellitus, arterial stiffness and cardiovascular disease: clinical implications and the influence of SGLT2i. Curr Vasc Pharmacol doi:10.2174/1570161118666200317150359 (2020).
   Web of Science ®Google Scholar
• Devineni D , PolidoriD. Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clin. Pharmacokinet., 54(10), 1027–1041 (2015).
   PubMed Web of Science ®Google Scholar
• Cefalu WT , LeiterLA, YoonKHet al. Efficacy and safety of canagliflozin versus glimepiride in patients with Type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, Phase III non-inferiority trial. Lancet, 382(9896), 941–950 (2013).
   PubMed Web of Science ®Google Scholar
• Davis SN . Canagliflozin versus glimepiride treatment in patients with Type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial). Expert Rev. Clin. Pharmacol., 7(1), 21–23 (2014).
   PubMed Web of Science ®Google Scholar
• Forst T , GuthrieR, GoldenbergRet al. Efficacy and safety of canagliflozin over 52 weeks in patients with Type 2 diabetes on background metformin and pioglitazone. Diabetes Obes. Metab., 16(5), 467–477 (2014).
   PubMed Web of Science ®Google Scholar
• Wilding JP , CharpentierG, HollanderPet al. Efficacy and safety of canagliflozin in patients with Type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int. J. Clin. Pract., 67(12), 1267–1282 (2013).
   PubMed Web of Science ®Google Scholar
• Stenlof K , CefaluWT, KimKAet al. Long-term efficacy and safety of canagliflozin monotherapy in patients with Type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr. Med. Res. Opin., 30(2), 163–175 (2014).
   PubMed Web of Science ®Google Scholar
• Blonde L , StenlofK, FungA, XieJ, CanovatchelW, MeiningerG. Effects of canagliflozin on body weight and body composition in patients with Type 2 diabetes over 104 weeks. Postgrad. Med., 128(4), 371–380 (2016).
   PubMed Web of Science ®Google Scholar
• Kosiborod M , CavenderMA, FuAZet al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL Study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation, 136(3), 249–259 (2017).
   PubMed Web of Science ®Google Scholar
• Kosiborod M , LamCSP, KohsakaSet al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL 2 study. J. Am. Coll. Cardiol., 71(23), 2628–2639 (2018).
   PubMed Web of Science ®Google Scholar
• Heerspink HJL , KarasikA, ThuressonMet al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol., 8(1), 27–35 (2020).
   PubMed Web of Science ®Google Scholar
• Ryan PB , BuseJB, SchuemieMJet al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with Type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes. Metab., 20(11), 2585–2597 (2018).
   PubMed Web of Science ®Google Scholar
• Udell JA , YuanZ, RyanPet al. Cardiovascular outcomes and mortality after initiation of canagliflozin: analyses from the EASEL Study. Endocrinol. Diabetes Metab., 3(1), e00096 (2020).
   PubMedGoogle Scholar
• Matthews DR , LiQ, PerkovicVet al. Effects of canagliflozin on amputation risk in Type 2 diabetes: the CANVAS Program. Diabetologia, 62(6), 926–938 (2019).
   PubMed Web of Science ®Google Scholar
• Yuan Z , DefalcoFJ, RyanPBet al. Risk of lower extremity amputations in people with Type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes. Metab., 20(3), 582–589 (2018).
   PubMed Web of Science ®Google Scholar
• Khouri C , CracowskiJL, RoustitM. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect?Diabetes Obes. Metab., 20(6), 1531–1534 (2018).
   PubMed Web of Science ®Google Scholar
• Perlman A , HeymanSN, MatokI, StokarJ, MuszkatM, SzalatA. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr. Metab. Cardiovasc. Dis., 27(12), 1108–1113 (2017).
   PubMed Web of Science ®Google Scholar
• Alba M , XieJ, FungA, DesaiM. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with Type 2 diabetes mellitus. Curr. Med. Res. Opin., 32(8), 1375–1385 (2016).
   PubMed Web of Science ®Google Scholar
• INVOKANA . https://www.ema.europa.eu/en/medicines/human/EPAR/invokana
   Google Scholar
• Medscape . 2018. EU Okays CV Benefit Labeling for Canagliflozin in Diabetes. https://www.medscape.com/viewarticle/902311
   Google Scholar